Multiple Assemblies exist for SMTL entry 5si9
Crystal Structure of human phosphodiesterase 10 in complex with 4-N-(2-hydroxyethyl)-2-methyl-3-N-(2-phenylimidazo[1,2-a]pyrimidin-7-yl)pyrazole-3,4-dicarboxamide; X-RAY DIFFRACTION 2.01 Å

	SMTL ID 5si9.1 Ligands ZINC ION; MAGNESIUM ION; N~4~-(2-hydroxyethyl)-1-methyl-N~5~-[(4R)-2-phenylimidazo[1,2-a]pyrimidin-7-yl]-1H-pyrazole-4,5-dicarboxamide Polypeptides cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Oligo-state monomer
	SMTL ID 5si9.2 Ligands ZINC ION; MAGNESIUM ION; N~4~-(2-hydroxyethyl)-1-methyl-N~5~-[(4R)-2-phenylimidazo[1,2-a]pyrimidin-7-yl]-1H-pyrazole-4,5-dicarboxamide Polypeptides cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Oligo-state monomer
	SMTL ID 5si9.3 Ligands ZINC ION; MAGNESIUM ION; N~4~-(2-hydroxyethyl)-1-methyl-N~5~-[(4R)-2-phenylimidazo[1,2-a]pyrimidin-7-yl]-1H-pyrazole-4,5-dicarboxamide Polypeptides cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Oligo-state monomer
	SMTL ID 5si9.4 Ligands ZINC ION; MAGNESIUM ION; N~4~-(2-hydroxyethyl)-1-methyl-N~5~-[(4R)-2-phenylimidazo[1,2-a]pyrimidin-7-yl]-1H-pyrazole-4,5-dicarboxamide Polypeptides cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Oligo-state monomer